The Australian Government Rural Industries and Research Development Corporation (RIRDC) has identified Tri-Solfen® (the Australian developed wound healing and pain management product for animals) as the number 1 registration priority for the Sheep, Cattle, Pig and Alpaca industries. The priority list was released on the RIRDC website www.rirdc.gov.au/agvet
Tri-Solfen®’s wound healing and pain relief technology addresses animal welfare concerns raised by major retailers and consumer groups regarding farming husbandry procedures in livestock, providing improved animal productivity, less pain, and resulting better welfare outcomes.
Tri-Solfen® has been proven effective in farm husbandry procedures such as tail docking, castration, dehorning, branding and other accidental wounds, further having the potential to reduce or eliminate the need for the use of antibiotics in the food chain that has traditionally occurred during some of these procedures. Currently Trisolfen is registered for the Australian sheep industry for routine fly strike surgery, treating 3 million merino lambs per annum.
“We are now working with livestock industry groups, the Australian Regulator (APVMA) and industry levy bodies ( MLA and AWI ) to ensure Tri-Solfen® is approved for use in other livestock procedures ” states Allan Giffard, Managing Director of Animal Ethics. “ Also, other countries have taken interest in our work, as we recently began work trialling Trisolfen in the EU with Portugal University on dehorning wound and pain management, so these issues are international and growing” says Giffard.
Animal Ethics Pty Ltd was also recently granted patents in the EU, USA, Canada and NZ, paving the way for the wound healing and pain relief technology to be commercialised in these international animal health markets.
– Ends –
About Medical Ethics
Medical Ethics is a commercial and development stage company focused on pain mitigation in wounds for humans and animals.
Through our proven patent protected platform technology, we have identified a transformational way of mitigating pain and minimising suffering associated with wounds.
Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.
Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286
Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000